Get the full picture
Sign in to uncover key details.
Retham Technologies
Manufacturing · Wisconsin, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1225 Discovery Pkwy, Wauwatosa, Wisconsi...Website
www.rethamtechnologies.comRevenue
<$5 MillionIndustry
About Retham Technologies
Retham Technologies is focused on revolutionizing the diagnosis and management of Heparin-induced Thrombocytopenia (HIT) through the development of a simple in vitro diagnostic (IVD) test. Established in 2017, the company aims to provide rapid and accurate HIT testing to improve patient outcomes and reduce healthcare costs. Their innovative assay is designed to facilitate timely and appropriate therapy for HIT-suspected patients, addressing the challenges of current diagnostic methods. Retham Technologies targets healthcare providers and hospitals that require efficient and reliable HIT diagnostic solutions.Explore more
Retham Technologies Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Retham Technologies
Compare insights from companies similar to Retham Technologies, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Retham Technologies
<$5M
1-10
Private
<$5M
-
Anand PadmanabhanChief Science Officer & Chief Medical Officer
Retham Technologies Tech Stack
A closer look at the technologies used by Retham Technologies
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Retham Technologies
Sign Up For FreeTo access detailed company insights
Retham Technologies is focused on revolutionizing the diagnosis and management of Heparin-induced Thrombocytopenia (HIT) through the development of a simple in vitro diagnostic (IVD) test. Established in 2017, the company aims to provide rapid and accurate HIT testing to improve patient outcomes and reduce healthcare costs. Their innovative assay i... Read More
